FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147041307> ?p ?o ?g. }

• W2147041307 endingPage "911" @default.
• W2147041307 startingPage "898" @default.
• W2147041307 abstract "Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental benefits across diverse regimens is less clear. The aim of our study was to estimate the magnitude of survival and disease progression benefits with the use of different regimens in patients with advanced colorectal cancer.We systematically reviewed randomised trials comparing systemic treatment regimens in advanced colorectal cancer. Treatment was categorised by use of or no use of fluorouracil-based regimens, irinotecan, oxaliplatin, bevacizumab, and cetuximab. We used multiple-treatment meta-analysis methodology to combine information from direct comparisons (ie, treatments compared within a randomised trial) and indirect comparisons (ie, treatments compared between trials by combining results on how effective they are against a common comparator treatment) of different chemotherapy regimens. The primary endpoint was death and the secondary endpoint was disease progression. Monte Carlo simulations were used to establish which regimen offered the most benefit for these endpoints. We did analyses of all trials and analysed separately trials that studied first-line treatments and non-first-line treatments.242 trials published in 1967-2007 (N=56 677 patients) involved 137 different chemotherapy regimens. 37 of these trials were eligible for the multiple-treatment meta-analysis, according to our categorisation, including 47 comparisons of data on death (N=13 875 patients) and 48 comparisons of data on disease progression (N=15 158 patients). Compared with fluorouracil plus leucovorin alone, the risk of death was most decreased with the addition of irinotecan plus bevacizumab (hazard ratio [HR] 0.60, 95% credibility intervals (CrI) 0.44-0.84) and considerable benefits were also noted with addition of irinotecan plus oxaliplatin (HR 0.72 [95% CrI 0.54-0.97]); oxaliplatin plus bevacizumab (HR 0.72 [0.57-0.90]); bevacizumab alone (HR 0.78 [0.60-1.03]); and oxaliplatin alone (HR 0.87 [0.78-0.98]). The disease progression benefits were even more prominent for the addition of irinotecan plus bevacizumab (HR 0.41 [0.28-0.60]); irinotecan plus oxaliplatin (0.53 [0.38-0.73]); oxaliplatin plus bevacizumab (0.46 [0.34-0.61]); bevacizumab alone (0.56 [0.41-0.76]); oxaliplatin alone (0.64 [0.56-0.73]); irinotecan plus cetuximab (HR 0.62 [0.42-0.92]); and irinotecan alone (HR 0.73 [0.65-0.82]). Findings were similar for first-line and non-first-line treatment analyses although data were sparse for non-first-line treatment analyses. Compared with a patient with an anticipated 1-year survival who is treated with fluorouracil and leucovorin, the absolute survival benefit is estimated at 8 months' prolongation with addition of irinotecan plus bevacizumab, 4.7 months' prolongation with addition of oxaliplatin plus bevacizumab or irinotecan plus oxaliplatin, and 1-1.8 months' prolongation with addition of irinotecan alone or oxaliplatin alone.Distinct incremental benefits are noted for diverse chemotherapy regimens in patients with advanced colorectal cancer, with more prominent effects on disease progression than on death. More data are needed at least for the newest drugs to estimate more accurately the magnitude of the benefit derived from their use." @default.
• W2147041307 created "2016-06-24" @default.
• W2147041307 creator A5019407121 @default.
• W2147041307 creator A5063853321 @default.
• W2147041307 creator A5070446713 @default.
• W2147041307 creator A5088217633 @default.
• W2147041307 date "2007-10-01" @default.
• W2147041307 modified "2023-09-27" @default.
• W2147041307 title "Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis" @default.
• W2147041307 cites W141482010 @default.
• W2147041307 cites W1840418402 @default.
• W2147041307 cites W1845706120 @default.
• W2147041307 cites W1870066362 @default.
• W2147041307 cites W1963782590 @default.
• W2147041307 cites W1965734230 @default.
• W2147041307 cites W1967385770 @default.
• W2147041307 cites W1968827386 @default.
• W2147041307 cites W1994869603 @default.
• W2147041307 cites W2005631828 @default.
• W2147041307 cites W2006824814 @default.
• W2147041307 cites W2009058749 @default.
• W2147041307 cites W2012852444 @default.
• W2147041307 cites W2037823066 @default.
• W2147041307 cites W2060305853 @default.
• W2147041307 cites W2061080795 @default.
• W2147041307 cites W2075642745 @default.
• W2147041307 cites W2076366897 @default.
• W2147041307 cites W2090025081 @default.
• W2147041307 cites W2097121246 @default.
• W2147041307 cites W2098803991 @default.
• W2147041307 cites W2099326967 @default.
• W2147041307 cites W2102601598 @default.
• W2147041307 cites W2103718021 @default.
• W2147041307 cites W2106845199 @default.
• W2147041307 cites W2109836271 @default.
• W2147041307 cites W2112727687 @default.
• W2147041307 cites W2112759697 @default.
• W2147041307 cites W2113053109 @default.
• W2147041307 cites W2114772012 @default.
• W2147041307 cites W2121368761 @default.
• W2147041307 cites W2123133140 @default.
• W2147041307 cites W2125328045 @default.
• W2147041307 cites W2125447919 @default.
• W2147041307 cites W2126827048 @default.
• W2147041307 cites W2126930838 @default.
• W2147041307 cites W2128403792 @default.
• W2147041307 cites W2128447158 @default.
• W2147041307 cites W2133399075 @default.
• W2147041307 cites W2133531206 @default.
• W2147041307 cites W2136055188 @default.
• W2147041307 cites W2140915063 @default.
• W2147041307 cites W2142564546 @default.
• W2147041307 cites W2143799188 @default.
• W2147041307 cites W2149469912 @default.
• W2147041307 cites W2156575195 @default.
• W2147041307 cites W2157769714 @default.
• W2147041307 cites W2159351246 @default.
• W2147041307 cites W2161095279 @default.
• W2147041307 cites W2161618993 @default.
• W2147041307 cites W2162313061 @default.
• W2147041307 cites W2162315065 @default.
• W2147041307 cites W2164906123 @default.
• W2147041307 cites W2170332580 @default.
• W2147041307 cites W2314927739 @default.
• W2147041307 cites W4236891330 @default.
• W2147041307 cites W2013937876 @default.
• W2147041307 doi "https://doi.org/10.1016/s1470-2045(07)70281-4" @default.
• W2147041307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17888735" @default.
• W2147041307 hasPublicationYear "2007" @default.
• W2147041307 type Work @default.
• W2147041307 sameAs 2147041307 @default.
• W2147041307 citedByCount "147" @default.
• W2147041307 countsByYear W21470413072012 @default.
• W2147041307 countsByYear W21470413072013 @default.
• W2147041307 countsByYear W21470413072014 @default.
• W2147041307 countsByYear W21470413072015 @default.
• W2147041307 countsByYear W21470413072016 @default.
• W2147041307 countsByYear W21470413072017 @default.
• W2147041307 countsByYear W21470413072018 @default.
• W2147041307 countsByYear W21470413072019 @default.
• W2147041307 countsByYear W21470413072020 @default.
• W2147041307 countsByYear W21470413072021 @default.
• W2147041307 countsByYear W21470413072022 @default.
• W2147041307 countsByYear W21470413072023 @default.
• W2147041307 crossrefType "journal-article" @default.
• W2147041307 hasAuthorship W2147041307A5019407121 @default.
• W2147041307 hasAuthorship W2147041307A5063853321 @default.
• W2147041307 hasAuthorship W2147041307A5070446713 @default.
• W2147041307 hasAuthorship W2147041307A5088217633 @default.
• W2147041307 hasConcept C121608353 @default.
• W2147041307 hasConcept C126322002 @default.
• W2147041307 hasConcept C143998085 @default.
• W2147041307 hasConcept C203092338 @default.
• W2147041307 hasConcept C2776694085 @default.
• W2147041307 hasConcept C2777802072 @default.
• W2147041307 hasConcept C2779998722 @default.
• W2147041307 hasConcept C2780259306 @default.
• W2147041307 hasConcept C2780739268 @default.

• next